Printer Friendly

Myriad Genetics obtains United States patent.

Myriad Genetics, Inc. (Salt Lake City, UT) has patented methods and materials used to isolate and detect human diabetes mellitus predisposing gene, specifically the angiotensinogen (AGT) gene, some mutant alleles of which cause susceptibility to insulin-dependent diabetes mellitus (IDDM). More specifically, the invention relates to germline mutations in the AGT gene and their use in the diagnosis of predisposition to diabetes. The invention also relates to the prophylaxis and/or therapy of diabetes associated with a mutation in the AGT gene. The invention further relates to the screening of drugs for diabetes therapy. Finally, the invention relates to the screening of the AGT gene for mutations, which are useful for diagnosing the predisposition to diabetes. (US 7,374,884)
COPYRIGHT 2008 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Jun 1, 2008
Previous Article:Proteome obtains isobaric mass labelling patent.
Next Article:Senomyx obtains United States patent.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters